Onconetix (ONCO) Non-Current Deferred Tax Liability (2021 - 2024)
Onconetix (ONCO) posted quarterly Non-Current Deferred Tax Liability of $2.9 million for Q3 2024, up 2.21% quarter-over-quarter from $2.8 million in Q2 2024.
Onconetix (ONCO) Non-Current Deferred Tax Liability (2021 - 2024) Analysis & Trends
Onconetix (ONCO) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $2.9 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.9 million; the TTM figure through Sep 2024 stood at $2.9 million (changed N/A YoY), while the FY2023 annual figure was $3.1 million, up 102188.89% from the prior year.
- Non-Current Deferred Tax Liability climbed to $2.9 million in Q3 2024 per ONCO's latest filing, from $2.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.1 million in Q4 2023 and bottomed at $2474.0 in Q4 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $1.9 million across 4 years, with a median of $2.8 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability rose 21.46% — and 2023, when it soared 102188.89%.
- Onconetix's Non-Current Deferred Tax Liability stood at $2474.0 in 2021, then grew by 21.46% to $3005.0 in 2022, then jumped by 102188.89% to $3.1 million in 2023, then retreated by 6.7% to $2.9 million in 2024.
- Business Quant data shows ONCO's Non-Current Deferred Tax Liability at $2.9 million in Q3 2024, $2.8 million in Q2 2024, and $2.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 3,005.00 |
| Dec 31, 2022 | 3,005.00 |
| Dec 31, 2021 | 2,474.00 |
| Dec 31, 2021 | 2,474.00 |